|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.28 USD | +0.01% |
|
+0.21% | +77.90% |
| 07-08 | Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says | MT |
| 06-25 | Major deals involving US drugmakers and biotechs over the past decade | RE |
| Market Cap | 10.08B 8.85B 8.23B 7.56B 14.2B 971B 14.42B 97.78B 38.2B 477B 37.85B 37.03B 1,650B | P/E 2026 * |
-31.1x | P/E 2027 * | -24.1x |
|---|---|---|---|---|---|
| Enterprise Value | 9.1B 7.99B 7.43B 6.82B 12.82B 877B 13.02B 88.28B 34.49B 431B 34.17B 33.43B 1,490B | EV / Sales 2026 * |
1,001x | EV / Sales 2027 * | 747x |
| Free-Float |
94.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Apogee Therapeutics, Inc.
| 1 day | +0.01% | ||
| 1 week | +0.21% | ||
| Current month | +1.17% | ||
| 1 month | +1.31% | ||
| 3 months | +56.85% | ||
| 6 months | +91.77% | ||
| Current year | +77.90% |
| 1 week | 134.02 |  | 134.4 |
| 1 month | 132.61 | | 134.4 |
| Current year | 60.35 | | 134.4 |
| 1 year | 34.34 | | 134.4 |
| 3 years | 14.19 | | 134.4 |
| 5 years | 14.19 | | 134.4 |
| 10 years | 14.19 | | 134.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 36 | 31/08/2022 | |
Jane Henderson
DFI | Director of Finance/CFO | 60 | 31/12/2022 |
Tim Piringer
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Fox
BRD | Director/Board Member | 54 | 21/06/2023 |
William Jones
BRD | Director/Board Member | 62 | 31/05/2023 |
| Director/Board Member | 36 | 31/05/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/07/26 | Don | Chief Technology Officer | -8,000 | 0.0143% | ||
| 10/07/26 | Don | Chief Executive Officer | -75,046 | 0.1340% | ||
| 01/07/26 | Fiscal year | Chief Technology Officer | 13,750 | 0.0246% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.01% | +0.21% | +228.96% | +538.52% | 10.08B | |
| +1.07% | -3.49% | -3.35% | +11.75% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +647.65% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +60.81% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.31% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +43.00% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.44% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.10% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -34.51% | 12.7B | |
| Average | +0.20% | +0.77% | +73.94% | +155.61% | 25.54B | |
| Weighted average by Cap. | +0.46% | +0.89% | +80.95% | +155.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.09M 7.98M 7.43M 6.81M 12.8M 875M 13M 88.18M 34.45M 430M 34.13M 33.39M 1.49B | 12.5M 10.98M 10.21M 9.37M 17.6M 1.2B 17.88M 121M 47.37M 592M 46.92M 45.91M 2.05B |
| Net income | -318M -279M -259M -238M -447M -30.58B -454M -3.08B -1.2B -15.03B -1.19B -1.17B -51.98B | -416M -366M -340M -312M -586M -40.1B -596M -4.04B -1.58B -19.72B -1.56B -1.53B -68.17B |
| Net Debt | -980M -860M -800M -734M -1.38B -94.33B -1.4B -9.5B -3.71B -46.37B -3.68B -3.6B -160B | -740M -650M -605M -555M -1.04B -71.28B -1.06B -7.18B -2.81B -35.05B -2.78B -2.72B -121B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | US$134.28 | +0.01% | 558,225 |
| 23/07/26 | US$134.26 | +0.13% | 691,294 |
| 22/07/26 | US$134.08 | -0.09% | 1,411,045 |
| 21/07/26 | US$134.20 | +0.04% | 428,085 |
| 20/07/26 | US$134.15 | +0.11% | 917,537 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- APGE Stock
Select your edition
All financial news and data tailored to specific country editions
